SCHEMBL4131207

SCHEMBL4131207

O=C(O)NCCc1cc(S(=O)(=O)c2cccnc2)n(-c2ccccc2F)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.40
HPGD P15428 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
ALDH1A1 P00352 4/20 0.38
CHRNB2 P17787 1/20 0.38
CHRNB4 P30926 1/20 0.38
CHRNA3 P32297 1/20 0.38
CHRNA4 P43681 1/20 0.38
SMN1; SMN2 Q16637 5/20 0.37
TSHR P16473 2/20 0.37
TP53 P04637 1/20 0.37
HSD17B10 Q99714 1/20 0.37
NAMPT P43490 5/20 0.36
USP2 O75604 1/20 0.35
ATM Q13315 1/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4131003 0.93 NAMPT (0.37) THRBHPGDL3MBTL1ALDH1A1CHRNB2
SCHEMBL4125815 0.93 ATM (0.36) THRBHPGDL3MBTL1ALDH1A1CHRNB2
SCHEMBL4135433 0.91 NAMPT (0.37) THRBALDH1A1CHRNB2CHRNB4CHRNA3
SCHEMBL4126977 0.91 NAMPT (0.38) THRBALDH1A1NAMPTATM
SCHEMBL4126106 0.90 NAMPT (0.40) ALDH1A1SMN1; SMN2NAMPTRAB9A
SCHEMBL4126103 0.89 ALDH1A1 (0.42) ALDH1A1SMN1; SMN2TSHRNAMPTMAPT
SCHEMBL4130432 0.88 NAMPT (0.39) THRBALDH1A1SMN1; SMN2HSD17B10NAMPT
SCHEMBL4123666 0.87 ALDH1A1 (0.38) ALDH1A1CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL4118135 0.86 NAMPT (0.42) ALDH1A1NAMPT
SCHEMBL4131436 0.85 NAMPT (0.38) ALDH1A1NAMPTATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2190822-B1 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2014-12-31 EP disclosed
US-20090156642-A1 5-Membered heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156642-A1 5-Membered heterocyclic compound CEL, PGA5, COG5 THRB 3537/4885HPGD 832/4885L3MBTL1 4714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.